Avid Bioservices Inc (CDMO)

[jakedogman1]

i don't think we see any value driver until the open label data is statistically significant and supports bavi. if and when that happens, i expect bp to make a play. and to fend bp off, mgmt needs support from shareholders and right now i doubt they could get much.


http://clinicaltrials.gov/ct2/show/NCT01160601?term=bavituximab&rank=4